What is HC Wainwright’s Estimate for NRXP FY2025 Earnings?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright raised their FY2025 EPS estimates for NRx Pharmaceuticals in a research note issued on Thursday, March 20th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.06) per share for the year, up from their prior forecast of ($0.07). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10).

NRXP has been the subject of several other reports. Ascendiant Capital Markets boosted their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. D. Boral Capital reissued a “buy” rating and set a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday.

NRx Pharmaceuticals Trading Down 2.9 %

NRx Pharmaceuticals stock opened at $2.01 on Monday. The firm has a market capitalization of $34.00 million, a P/E ratio of -0.94 and a beta of 1.22. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock’s fifty day simple moving average is $2.70 and its 200-day simple moving average is $2.04.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently modified their holdings of NRXP. AdvisorShares Investments LLC raised its stake in NRx Pharmaceuticals by 138.5% in the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock valued at $683,000 after buying an additional 180,229 shares in the last quarter. Anson Funds Management LP increased its holdings in shares of NRx Pharmaceuticals by 30.3% in the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after acquiring an additional 43,135 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth about $61,000. Squarepoint Ops LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter worth approximately $56,000. Finally, Townsquare Capital LLC acquired a new position in NRx Pharmaceuticals in the third quarter valued at approximately $25,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.